Drug Design Development and Therapy2017Open Access

Regulation profile of the intestinal peptide transporter 1 (PepT1)

Chunyang Wang, Shu Liu, Xiao-Nv Xie et al.

96 citations2017Open Access — see publisher for license terms1 related compound

Research Article — Peer-Reviewed Source

Original research published by Wang et al. in Drug Design Development and Therapy. Redistributed under Open Access — see publisher for license terms. MedTech Research Group provides these references for informational purposes. We do not conduct original research. All studies are the work of their respective authors and institutions.

Abstract

The intestinal peptide transporter 1 (PepT1) was first identified in 1994. It plays a crucial role in the absorption of small peptides including not only >400 different dipeptides and 8,000 tripeptides digested from dietary proteins but also a repertoire of structurally related compounds and drugs. Owing to its critical role in the bioavailability of peptide-like drugs, such as the anti-cancer agents and anti-virus drug, PepT1 is increasingly becoming a striking prodrug-designing target. Therefore, the understanding of PepT1 gene regulation is of great importance both for dietary adaptation and for clinical drug treatment. After decades of research, it has been recognized that PepT1 could be regulated at the transcriptional and post-transcriptional levels by numerous factors. Therefore, the present review intends to summarize the progress made in the regulation of PepT1 and provide insights into the PepT1's potential in clinical aspects of nutritional and drug therapies.

Full Text

Full text is available at the publisher.

Read at Publisher
Article Details
DOI10.2147/dddt.s151725
JournalDrug Design Development and Therapy
Year2017
AuthorsChunyang Wang, Shu Liu, Xiao-Nv Xie, Zhi‐Rong Tan
LicenseOpen Access — see publisher for license terms
Citations96